Bevacizumab at Half the Standard Dose Equivalent to Standard Dosing for Glioblastoma

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the Journal of Neuro-Oncology, researchers from Northern California Kaiser Permanente hospitals have found that dosing bevacizumab at half the standard dose for the treatment of patients with progressive or recurrent glioblastoma multiforme had similar or possibly better efficacy than standard dosing.

The standard dose of bevacizumab is 10mg/kg every 2 weeks for patients with progressive glioblastoma multiforme; however, bevacizumab has only been found to produce improved objective responses, not improved survival.

Because institutions use varying dose schedules, such as 7.5mg/kg every 3 to 4 weeks, researchers conducted a retrospective study to assess effect of various approaches to bevacizumab dosing on overall survival.

Researchers identified 181 patients who received bevacizumab between September 1, 2008 and August 31, 2013. Patients had a median AUC of 3.6mg·wk/kg. Analyses showed that women lived longer than men (P = 0.002), patients older than than 65 years fared worse than younger patients (P = 0.004), and patients treated with less bevacizumab than 3.6mg·wk/kg did better than patients treated above 3.6mg·wk/kg (P = 0.003).

In addition, the median overall survival for patients who started bevacizumab 1 month after chemoradiation was 45 weeks compared with 68 weeks (P = 0.012), and 40 weeks versus 74 weeks (P = 0.0085) for those who started 3 months after chemoradiation.

Successful First Step for Vaccine Targeting Brain Cancer Mutation
Bevacizumab at half the standard dose for the treatment of patients with progressive or recurrent glioblastoma.
The authors aim to investigate the impact of bevacizumab (BEV) administered dose on median overall survival (mOS) of patients with progressive glioblastoma (GBM). Dosing BEV at half the standard dose for progressive/recurrent GBM was at least equivalent to or, maybe better than standard dosing.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs